Upstream Bio, Inc. (UPB)

↓ Download CSV

CIK 0002022626 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Upstream Bio, Inc. reported revenue of $2.85M, up 20.4% from the prior year. The company ran a net loss, with a net margin of -5026.0%. It held $353.77M in total assets against $14.00M in total liabilities.

Key ratios (FY2025)

-5618.8%
Operating margin
-5026.0%
Net margin
-42.2%
Return on equity
+20.4%
Revenue growth (YoY)
Metric (FY)2025202420232022
Revenue$2.85M$2.37M$2.38M
Operating Income-$160.36M-$77.76M-$40.11M
Net Income-$143.44M-$62.81M-$20.54M
EPS (Diluted)$-2.66$-5.58$-12.95
Total Assets$353.77M$481.72M$117.20M
Total Liabilities$14.00M$11.87M$9.39M
Shareholders' Equity$339.77M$469.85M-$123.13M-$106.16M
Cash & Equivalents$101.58M$325.89M$25.83M
Operating Cash Flow-$133.28M-$59.17M-$37.93M
Capital Expenditures$165.0K$511.0K$144.0K
Shares Outstanding54.24M53.60M2.99M